vs
科睿唯安（CLVT）与D-Wave Quantum Inc.（QBTS）财务数据对比。点击上方公司名可切换其他公司
科睿唯安的季度营收约是D-Wave Quantum Inc.的224.2倍（$617.0M vs $2.8M）。科睿唯安净利率更高（0.5% vs -1538.0%，领先1538.5%）。D-Wave Quantum Inc.同比增速更快（19.2% vs -6.9%）。科睿唯安自由现金流更多（$89.2M vs $-20.0M）。过去两年D-Wave Quantum Inc.的营收复合增速更高（5.7% vs -0.3%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
D-Wave量子公司是专注量子计算领域的科技企业，在美国加利福尼亚州帕洛阿尔托、加拿大不列颠哥伦比亚省本拿比均设有办公点。该公司自称是全球首家销售基于量子效应运行的计算机的企业，客户包括洛克希德·马丁、南加州大学、谷歌与NASA联合项目、洛斯阿拉莫斯国家实验室等。
CLVT vs QBTS — 直观对比
营收规模更大
CLVT
是对方的224.2倍
$2.8M
营收增速更快
QBTS
高出26.1%
-6.9%
净利率更高
CLVT
高出1538.5%
-1538.0%
自由现金流更多
CLVT
多$109.2M
$-20.0M
两年增速更快
QBTS
近两年复合增速
-0.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $617.0M | $2.8M |
| 净利润 | $3.1M | $-42.3M |
| 毛利率 | 66.8% | 64.8% |
| 营业利润率 | 6.7% | -1266.0% |
| 净利率 | 0.5% | -1538.0% |
| 营收同比 | -6.9% | 19.2% |
| 净利润同比 | 101.6% | 50.8% |
| 每股收益（稀释后） | $0.00 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTQBTS
| Q4 25 | $617.0M | $2.8M | ||
| Q3 25 | $623.1M | $3.7M | ||
| Q2 25 | $621.4M | $3.1M | ||
| Q1 25 | $593.7M | $15.0M | ||
| Q4 24 | $663.0M | $2.3M | ||
| Q3 24 | $622.2M | $1.9M | ||
| Q2 24 | $650.3M | $2.2M | ||
| Q1 24 | $621.2M | $2.5M |
净利润CLVTQBTS
| Q4 25 | $3.1M | $-42.3M | ||
| Q3 25 | $-28.3M | $-140.0M | ||
| Q2 25 | $-72.0M | $-167.3M | ||
| Q1 25 | $-103.9M | $-5.4M | ||
| Q4 24 | $-191.8M | $-86.1M | ||
| Q3 24 | $-65.6M | $-22.7M | ||
| Q2 24 | $-304.3M | $-17.8M | ||
| Q1 24 | $-75.0M | $-17.3M |
毛利率CLVTQBTS
| Q4 25 | 66.8% | 64.8% | ||
| Q3 25 | 65.0% | 71.4% | ||
| Q2 25 | 67.2% | 63.8% | ||
| Q1 25 | 65.1% | 92.5% | ||
| Q4 24 | 65.7% | 63.8% | ||
| Q3 24 | 66.2% | 55.8% | ||
| Q2 24 | 67.2% | 63.6% | ||
| Q1 24 | 64.9% | 67.3% |
营业利润率CLVTQBTS
| Q4 25 | 6.7% | -1266.0% | ||
| Q3 25 | 7.1% | -741.8% | ||
| Q2 25 | 1.1% | -856.3% | ||
| Q1 25 | -3.5% | -75.3% | ||
| Q4 24 | -9.4% | -876.2% | ||
| Q3 24 | 3.5% | -1103.5% | ||
| Q2 24 | -36.9% | -863.0% | ||
| Q1 24 | 0.8% | -710.6% |
净利率CLVTQBTS
| Q4 25 | 0.5% | -1538.0% | ||
| Q3 25 | -4.5% | -3743.9% | ||
| Q2 25 | -11.6% | -5406.4% | ||
| Q1 25 | -17.5% | -36.1% | ||
| Q4 24 | -28.9% | -3727.9% | ||
| Q3 24 | -10.5% | -1214.5% | ||
| Q2 24 | -46.8% | -814.4% | ||
| Q1 24 | -12.1% | -702.3% |
每股收益（稀释后）CLVTQBTS
| Q4 25 | $0.00 | $-0.13 | ||
| Q3 25 | $-0.04 | $-0.41 | ||
| Q2 25 | $-0.11 | $-0.55 | ||
| Q1 25 | $-0.15 | $-0.02 | ||
| Q4 24 | $-0.27 | $-0.43 | ||
| Q3 24 | $-0.09 | $-0.11 | ||
| Q2 24 | $-0.46 | $-0.10 | ||
| Q1 24 | $-0.14 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $329.2M | $884.5M |
| 总债务越低越好 | $4.3B | — |
| 股东权益账面价值 | $4.8B | $852.2M |
| 总资产 | $11.1B | $915.8M |
| 负债/权益比越低杠杆越低 | 0.89× | — |
8季度趋势，按日历期对齐
现金及短期投资CLVTQBTS
| Q4 25 | $329.2M | $884.5M | ||
| Q3 25 | $318.7M | $836.2M | ||
| Q2 25 | $362.6M | $819.3M | ||
| Q1 25 | $354.0M | $304.3M | ||
| Q4 24 | $295.2M | $178.0M | ||
| Q3 24 | $388.5M | — | ||
| Q2 24 | $376.4M | — | ||
| Q1 24 | $361.8M | — |
总债务CLVTQBTS
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $4.6B | — | ||
| Q1 24 | $4.6B | — |
股东权益CLVTQBTS
| Q4 25 | $4.8B | $852.2M | ||
| Q3 25 | $4.9B | $670.6M | ||
| Q2 25 | $5.0B | $694.3M | ||
| Q1 25 | $5.0B | $207.4M | ||
| Q4 24 | $5.1B | $62.6M | ||
| Q3 24 | $5.5B | $-16.9M | ||
| Q2 24 | $5.6B | $-21.5M | ||
| Q1 24 | $5.9B | $-37.0M |
总资产CLVTQBTS
| Q4 25 | $11.1B | $915.8M | ||
| Q3 25 | $11.2B | $865.8M | ||
| Q2 25 | $11.4B | $843.6M | ||
| Q1 25 | $11.5B | $325.6M | ||
| Q4 24 | $11.5B | $199.9M | ||
| Q3 24 | $12.0B | $49.6M | ||
| Q2 24 | $12.1B | $61.8M | ||
| Q1 24 | $12.5B | $48.6M |
负债/权益比CLVTQBTS
| Q4 25 | 0.89× | — | ||
| Q3 25 | 0.90× | — | ||
| Q2 25 | 0.90× | — | ||
| Q1 25 | 0.90× | — | ||
| Q4 24 | 0.88× | — | ||
| Q3 24 | 0.84× | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | 0.79× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $159.9M | $-18.4M |
| 自由现金流经营现金流 - 资本支出 | $89.2M | $-20.0M |
| 自由现金流率自由现金流/营收 | 14.5% | -727.9% |
| 资本支出强度资本支出/营收 | 11.5% | 60.3% |
| 现金转化率经营现金流/净利润 | 51.58× | — |
| 过去12个月自由现金流最近4个季度 | $365.3M | $-75.8M |
8季度趋势，按日历期对齐
经营现金流CLVTQBTS
| Q4 25 | $159.9M | $-18.4M | ||
| Q3 25 | $181.1M | $-19.0M | ||
| Q2 25 | $116.3M | $-15.3M | ||
| Q1 25 | $171.2M | $-19.3M | ||
| Q4 24 | $141.3M | $2.0M | ||
| Q3 24 | $202.9M | $-18.1M | ||
| Q2 24 | $126.2M | $-14.5M | ||
| Q1 24 | $176.2M | $-12.1M |
自由现金流CLVTQBTS
| Q4 25 | $89.2M | $-20.0M | ||
| Q3 25 | $115.5M | $-20.1M | ||
| Q2 25 | $50.3M | $-16.0M | ||
| Q1 25 | $110.3M | $-19.7M | ||
| Q4 24 | $59.1M | $1.1M | ||
| Q3 24 | $126.3M | $-18.4M | ||
| Q2 24 | $60.3M | $-15.0M | ||
| Q1 24 | $111.8M | $-12.4M |
自由现金流率CLVTQBTS
| Q4 25 | 14.5% | -727.9% | ||
| Q3 25 | 18.5% | -536.5% | ||
| Q2 25 | 8.1% | -518.1% | ||
| Q1 25 | 18.6% | -131.4% | ||
| Q4 24 | 8.9% | 46.2% | ||
| Q3 24 | 20.3% | -982.8% | ||
| Q2 24 | 9.3% | -687.7% | ||
| Q1 24 | 18.0% | -504.0% |
资本支出强度CLVTQBTS
| Q4 25 | 11.5% | 60.3% | ||
| Q3 25 | 10.5% | 27.2% | ||
| Q2 25 | 10.6% | 24.2% | ||
| Q1 25 | 10.3% | 2.9% | ||
| Q4 24 | 12.4% | 41.1% | ||
| Q3 24 | 12.3% | 16.4% | ||
| Q2 24 | 10.1% | 25.0% | ||
| Q1 24 | 10.4% | 12.4% |
现金转化率CLVTQBTS
| Q4 25 | 51.58× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Academia Government Group | $312.3M | 51% |
| Re Occurring Revenues | $114.1M | 18% |
| Life Sciences And Healthcare Group | $98.3M | 16% |
| Transactional Revenues | $97.1M | 16% |
QBTS
暂无分部数据
